{
    "Trade/Device Name(s)": [
        "\u03bcTASWako i30 Immunoanalyzer System",
        "\u03bcTASWako AFP-L3 Immunological Test System",
        "\u03bcTASWako DCP Immunological Test System",
        "\u03bcTASWako AFP-L3 Calibrator Set",
        "\u03bcTASWako AFP-L3 Control L",
        "\u03bcTASWako AFP-L3 Control H",
        "\u03bcTASWako DCP Calibrator Set",
        "\u03bcTASWako DCP Control L",
        "\u03bcTASWako DCP Control H"
    ],
    "Submitter Information": "Wako Chemicals, USA, Inc. Wako Diagnostics",
    "510(k) Number": "K100464",
    "Predicate Device Reference 510(k) Number(s)": [
        "K041847",
        "K062368"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NSF",
        "OAU",
        "OUE",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "February 14, 2011",
    "Summary Letter Received Date": "February 15, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR866.6030"
    ],
    "Regulation Name(s)": [
        "AFP-L3% Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "AFP-L3%",
        "DCP",
        "Total AFP"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "\u03bcTASWako i30 Immunoanalyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochemical techniques",
        "Automated fluorescence analyzer",
        "Microfluidic chip technology"
    ],
    "Methodologies": [
        "Quantitative immunoassay",
        "Fluorescence detection",
        "Electrophoresis separation"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay",
        "Calibrator",
        "Control",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for \u03bcTASWako i30 Immunoanalyzer System and associated AFP-L3 and DCP immunological test systems for quantitative measurement of AFP-L3% and DCP in human serum",
    "Indications for Use Summary": "Intended for quantitative measurement of AFP-L3% and DCP in human serum as aids in risk assessment of hepatocellular carcinoma in patients with chronic liver disease, used with the \u03bcTASWako i30 Immunoanalyzer",
    "fda_folder": "Immunology"
}